Cited by 1,145Schizophrenia research and treatmentPharmacology and Obesity TreatmentHIV-related health complications and treatments

The DOI matches its Crossref record; 130 of the 131 references it cites were found in a registry or an index.

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

De Hert, Marc, Detraux, Johan, van Winkel, Ruud, Yu, Weiping, Correll, Christoph U.·2012·Nature Reviews Endocrinology

DOI 10.1038/nrendo.2011.156

Open this paper in CoChat — free account

Abstract

Antipsychotic medications can induce cardiovascular and metabolic abnormalities (such as obesity, hyperglycemia, dyslipidemia and the metabolic syndrome) that are associated with an increased risk of type 2 diabetes mellitus and cardiovascular disease. Controversy remains about the contribution of individual antipsychotic drugs to this increased risk and whether they cause sudden cardiac death through prolongation of the corrected QT interval. Although some drug receptor-binding affinities correlate with specific cardiovascular and metabolic abnormalities, the exact pharmacological mechanisms underlying these associations remain unclear. Antipsychotic agents with prominent metabolic adverse effects might cause abnormalities in glucose and lipid metabolism via both obesity-related and obesity-unrelated molecular mechanisms. Despite existing guidelines and recommendations, many antipsychotic-drug-treated patients are not assessed for even the most easily measurable metabolic and cardiac risk factors, such as obesity and blood pressure. Subsequently, concerns have been raised over the use of these medications, especially pronounced in vulnerable pediatric patients, among whom their use has increased markedly in the past decade and seems to have especially orexigenic effects. This Review outlines the metabolic and cardiovascular risks of various antipsychotic medications in adults and children, defines the disparities in health care and finally makes recommendations for screening and monitoring of patients taking these agents.

Integrity signals

Registry

Crossref · 10.1038/nrendo.2011.156

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Bipolar Disorder
Yatham, L. N., & Malhi, G. S. (2011) · Oxford University Press eBooks · doi:10.1093/med/9780199562305.001.0001 · Cited by 3,515
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Systematic review and meta-analysis
Gillies, A. (2019) · CRC Press eBooks · doi:10.1201/9781315377315-19 · Cited by 2,876
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
A Population-Based Study
Christakis, D., Richards, J. A., Zimmerman, F. J., Garrison, M. M., Xu, D., & Yapanel, U. H. (2009) · Cited by 2,290
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., CHAITMAN, B. R., FROMER, M. A., Gregoratos, G., Klein, G. J., Myerburg, R. J., Quiñones, M. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.010 · Cited by 1,975
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Second-Generation (Atypical) Antipsychotics and Metabolic Effects
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,352
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., LAUGHREN, T. P., & Katz, R. G. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204
Atypical antipsychotic drugs and the risk of sudden cardiac death
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194
Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis
Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & Binder, M. D. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr148 · Cited by 1,120
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Schizophrenia and increased risks of cardiovascular disease
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.007 · Cited by 1,070
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050
Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N. H., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs
Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P. R., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 803
International Diabetes Federation: a consensus on Type 2 diabetes prevention
Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02157.x · Cited by 778
Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition
(2007) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890423363.45859 · Cited by 735
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
Nasrallah, H. A. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002066 · Cited by 718
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 698
Metabolic Syndrome: Connecting and Reconciling Cardiovascular and Diabetes Worlds
Grundy, S. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.046 · Cited by 686
Metabolic syndrome in people with schizophrenia: a review
DE HERT, M., SCHREURS, V., VANCAMPFORT, D., & VAN WINKEL, R. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00199.x · Cited by 634
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline
Nasrallah, H. A., Meyer, J. M., GOFF, D. C., McEvoy, J. P., Thomas, S., Stroup, T. S., & Lieberman, J. A. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.026 · Cited by 563
A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia
Leucht, S., Komossa, K., Rummel‐Kluge, C., Corves, C., Hunger, H., Schmid, F., Lobos, C. A., Schwarz, S., & Davis, J. M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 499
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.
Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry
Mojtabai, R., & Olfson, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.175 · Cited by 479
Schizophrenia, just the facts
Wyatt, R. J., Alexander, R., Egan, M. F., & Kirch, D. G. (1988) · Schizophrenia Research · doi:10.1016/0920-9964(88)90034-5 · Cited by 478
Adverse Effects of Atypical Antipsychotics
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 468
Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms
Reynolds, G. P., & Kirk, S. L. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.010 · Cited by 422
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 405
Antipsychotic drug-induced weight gain mediated by histamine H 1 receptor-linked activation of hypothalamic AMP-kinase
Kim, S. F., Huang, A. S., Snowman, A. M., Teuscher, C., & Snyder, S. H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611417104 · Cited by 394
Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice
Hert, M. A. F. D., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2010.09.011 · Cited by 365
Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices
Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012) · Psychological Medicine · doi:10.1017/s003329171100105x · Cited by 332
Self-citation
Antipsychotic drugs and obesity
Correll, C. U., Lencz, T., & Malhotra, A. K. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.010 · Cited by 315
Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing
Vetter, V. L., Elia, J., Erickson, C., Berger, S., Blum, N., Uzark, K., & Webb, C. L. (2008) · Circulation · doi:10.1161/circulationaha.107.189473 · Cited by 296
Systematic Review of Early Cardiometabolic Outcomes of the First Treated Episode of Psychosis
Foley, D. L., & Morley, K. I. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2 · Cited by 283
From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics
Correll, C. U. (2010) · European Psychiatry · doi:10.1016/s0924-9338(10)71701-6 · Cited by 277
Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons
Rummel‐Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq042 · Cited by 275
First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis
Smith, M. J., Hopkins, D., Peveler, R., Holt, R. I. G., Woodward, M., & Ismail, K. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037184 · Cited by 274
Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder
Laursen, T. M., Munk-Olsen, T., Agerbo, E., Gasse, C., & Mortensen, P. B. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.61 · Cited by 271
Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders
Álvarez‐Jiménez, M., González‐Blanch, C., Crespo‐Facorro, B., Hetrick, S. E., Rodríguez-Sánchez, J. M., Pérez‐Iglesias, R., & Vázquez‐Barquero, J. L. (2008) · CNS Drugs · doi:10.2165/00023210-200822070-00002 · Cited by 271
Antipsychotics and the Risk of Sudden Cardiac Death
Straus, S. M. J. M., Bleumink, G. S., Dieleman, J. P., van der Lei, J., Jong, G. W. ‘., Kingma, J. H., Sturkenboom, M., & Stricker, B. H. C. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.12.1293 · Cited by 262
Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: Cohort study using administrative data
Hennessy, S., Bilker, W. B., Knauss, J. S., Margolis, D. J., Kimmel, S. E., Reynolds, R. F., Glasser, D. B., Morrison, M. F., & Strom, B. L. (2002) · BMJ · doi:10.1136/bmj.325.7372.1070 · Cited by 261
Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo‐controlled trials
Correll, C. U., Sheridan, E. M., & DelBello, M. P. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00798.x · Cited by 255
National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007
Comer, J. S., Olfson, M., & Mojtabai, R. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.07.007 · Cited by 253
Use of waist circumference to predict insulin resistance: retrospective study
Wahrenberg, H., Hertel, K., Leijonhufvud, B.-M., Persson, L., Toft, E., & Arner, P. (2005) · BMJ · doi:10.1136/bmj.38429.473310.ae · Cited by 242
Past and Present Progress in the Pharmacologic Treatment of Schizophrenia
Kane, J. M., & Correll, C. U. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06264yel · Cited by 239
Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent?
Simon, V., van Winkel, R., & Binder, M. D. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04392 · Cited by 239
Systematic Review and Metaanalysis
Shimada, T., Noguchi, Y., Jackson, J. L., Miyashita, J., Hayashino, Y., Kamiya, T., Yamazaki, S., Matsumura, T., & Fukuhara, S. (2009) · CHEST Journal · doi:10.1378/chest.08-2602 · Cited by 239
Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis
Maayan, L. A., Vakhrusheva, J., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.21 · Cited by 230
Combining Risk Estimates from Observational Studies with Different Exposure Cutpoints: A Meta-analysis on Body Mass Index and Diabetes Type 2
Hartemink, N., Boshuizen, H. C., Nagelkerke, N. J. D., Jacobs, M. A. M., & van Houwelingen, H. C. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj141 · Cited by 226
Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation
Hert, M. A. F. D., Vancampfort, D., Correll, C. U., Mercken, V., Peuskens, J., Sweers, K., van Winkel, R., & Mitchell, A. J. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.084665 · Cited by 226
Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons
Fraguas, D., Correll, C. U., Merchán‐Naranjo, J., Rapado‐Castro, M., Parellada, M., Moreno, C., & Arango, C. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.07.002 · Cited by 209
Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naïve Schizophrenia Patients
Nielsen, J., Skadhede, S., & Correll, C. U. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.78 · Cited by 207
Self-citation
Waist Circumference Measurement in Clinical Practice
Ness-Abramof, R., & Apovian, C. M. (2008) · Nutrition in Clinical Practice · doi:10.1177/0884533608321700 · Cited by 205
The effects of undertreated chronic medical illnesses in patients with severe mental disorders.
Fagiolini, A., & Goracci, A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.7075su1c.04 · Cited by 205
Metabolic Testing Rates in 3 State Medicaid Programs After FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs
Morrato, E. H., Druss, B. G., Hartung, D. M., Valuck, R. J., Allen, R. R., Campagna, E. J., & Newcomer, J. W. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.179 · Cited by 199
Weight effects associated with antipsychotics: A comprehensive database analysis
Parsons, B., Allison, D. B., Loebel, A. D., Williams, K., Giller, E. L., Romano, S. J., & SIU, C. O. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.025 · Cited by 193
Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents
Correll, C. U., Penzner, J. B., Parikh, U. H., Mughal, T., Javed, T., Carbon, M., & Malhotra, A. K. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.007 · Cited by 187
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder
van Winkel, R., Binder, M. D., Eyck, D. V., Hanssens, L., Wampers, M., Scheen, A. J., & Peuskens, J. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00520.x · Cited by 185
Inequitable access for mentally ill patients to some medically necessary procedures
Kisely, S., Smith, M., Lawrence, D., Cox, M., Campbell, L. A., & Maaten, S. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060482 · Cited by 185
Systematic Review and Meta‐Analysis
Bouter, L. M., Zeegers, M., & Lee, T. (2023) · Wiley eBooks · doi:10.1002/9781394323104.ch11 · Cited by 183
Prevalence and Predictors of Lipid and Glucose Monitoring in Commercially Insured Patients Treated With Second-Generation Antipsychotic Agents
Haupt, D. W., Rosenblatt, L. C., Kim, E., Baker, R. A., Whitehead, R. E., & Newcomer, J. W. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030383 · Cited by 180
Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
McIntyre, R., & Jerrell, J. (2008) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.162.10.929 · Cited by 177
Treatment and Prevention
Whitaker, L. C. (1992) · Springer eBooks · doi:10.1007/978-1-4757-2159-1_10 · Cited by 174
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Holt, R. I. G. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2086 · Cited by 171
Cardiovascular Monitoring and Stimulant Drugs for Attention-Deficit/Hyperactivity Disorder
Perrin, J. M., Friedman, R. A., Knilans, T. K., the Black Box Working Group, & Surgery, T. S. O. C. A. C. (2008) · Pediatrics · doi:10.1542/peds.2008-1573 · Cited by 161
Thioridazine and sudden unexplained death in psychiatric in-patients
Reilly, J. G., Ayis, S. A., Ferrier, I. N., Jones, S., & Thomas, S. (2002) · The British Journal of Psychiatry · doi:10.1192/bjp.180.6.515 · Cited by 157
Treatment with antipsychotics and the risk of diabetes in clinical practice
Kessing, L. V., Thomsen, A. F., Mogensen, U. B., & Andersen, P. K. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.076935 · Cited by 152
Metabolic Screening in Children Receiving Antipsychotic Drug Treatment
Morrato, E. H., Nicol, G. E., Maahs, D. M., Druss, B. G., Hartung, D. M., Valuck, R. J., Campagna, E. J., & Newcomer, J. W. (2010) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpediatrics.2010.48 · Cited by 149
Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design
Coccurello, R., & Moles, A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.008 · Cited by 147
A UK Audit of Screening for the Metabolic Side Effects of Antipsychotics in Community Patients
Barnes, T. R. E., Paton, C., Cavanagh, M.-R., Hancock, E., Taylor, D. M., & Health, O. B. O. T. U. P. O. F. M. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm038 · Cited by 145
Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes
Silvestre, J. S., & Prous, J. (2005) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2005.27.5.908643 · Cited by 142
Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia
Vancampfort, D., Probst, M., Sweers, K., Maurissen, K., Knapen, J., & Hert, M. A. F. D. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01666.x · Cited by 139
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis
Strassnig, M., Miewald, J. M., Keshavan, M. S., & Ganguli, R. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.02.024 · Cited by 135
Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder
Maina, G., Salvi, V., Vitalucci, A., D’Ambrosio, V., & Bogetto, F. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.12.233 · Cited by 135
Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia
Vancampfort, D., Knapen, J., Probst, M., van Winkel, R., Deckx, S., Maurissen, K., Peuskens, J., & Binder, M. D. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.03.011 · Cited by 134
Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data
Li, Q., Knol, M. J., Corpeleijn, E., & Stolk, R. P. (2009) · European Journal of Epidemiology · doi:10.1007/s10654-009-9395-y · Cited by 132
Management of antipsychotic-related weight gain
Maayan, L. A., & Correll, C. U. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.85 · Cited by 132
Comparative Mortality Associated With Ziprasidone and Olanzapine in Real-World Use Among 18,154 Patients With Schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC)
Strom, B. L., Eng, S. M., Faich, G., Reynolds, R. F., D'Agostino, R. B., Ruskin, J., & Kane, J. M. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.08040484 · Cited by 122
Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics
Hasnain, M., Fredrickson, S. K., Vieweg, W. V. R., & Pandurangi, A. K. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0112-8 · Cited by 121
Treatment of ischaemic heart disease and stroke in individuals with psychosis under universal healthcare
Kisely, S., Campbell, L. A., & Wang, Y. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.067082 · Cited by 116
Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care
Lambert, T. J. R., & Newcomer, J. W. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02374.x · Cited by 115
Weight gain in antipsychotic-naive patients: a review and meta-analysis
Tarricone, I., Gozzi, B. F., Serretti, A., Grieco, D., & Berardi, D. (2009) · Psychological Medicine · doi:10.1017/s0033291709990407 · Cited by 113
The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study
Yood, M. U., DeLorenze, G. N., Quesenberry, C. P., Oliveria, S. A., Tsai, A., Willey, V. J., McQuade, R. D., Newcomer, J. W., & L'Italien, G. J. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1781 · Cited by 106
Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study
Hippisley‐Cox, J., Parker, C., Coupland, C. A. C., & Vinogradova, Y. (2007) · Heart · doi:10.1136/hrt.2006.110171 · Cited by 106
How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins
Starrenburg, F. C. J., & Bogers, J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.001 · Cited by 100
MTHFR and risk of metabolic syndrome in patients with schizophrenia
van Winkel, R., Rutten, B. P. F., Peerbooms, O., Peuskens, J., van Os, J., & Binder, M. D. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.030 · Cited by 94
A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study
Arango, C., Bobes, J., Aranda, P., Carmena, R., García-García, M., & Rejas, J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.05.009 · Cited by 93
Cardiovascular aspects of antipsychotics
Raedler, T. J. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32833f46c9 · Cited by 89
Cost-Effective Screening for the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotic Medications
Straker, D., Correll, C. U., Kramer‐Ginsberg, E., Abdulhamid, N., Koshy, F., Rubens, E. O., Saint-Vil, R., Kane, J. M., & Manu, P. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.6.1217 · Cited by 89
The association between weight change and symptom reduction in the CATIE schizophrenia trial
Hermes, E. D. A., Nasrallah, H. A., Davis, V. G., Meyer, J. M., McEvoy, J. P., GOFF, D. C., Thomas, S., Stroup, T. S., Swartz, M. S., Lieberman, J. A., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.01.022 · Cited by 87
Quality of Care for Cardiovascular Disease-related Conditions in Patients with and without Mental Disorders
Kilbourne, A. M., Welsh, D. E., McCarthy, J. F., Post, E. P., & Blow, F. C. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0720-z · Cited by 86
Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: A population-based study
Liao, C.-H., Chang, C.-S., Wei, W.-C., Chang, S., Liao, C., Lane, H., & Sung, F.-C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.12.007 · Cited by 82
Sudden deaths in psychiatric patients
Manu, P., Kane, J. M., & Correll, C. U. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06244gry · Cited by 80
Self-citation
Adverse events in children and adolescents treated with antipsychotic medications
Jerrell, J. M., & McIntyre, R. S. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.932 · Cited by 80
Do Certain Atypical Antipsychotics Increase the Risk of Diabetes? A Critical Review of 17 Pharmacoepidemiologic Studies
Ramaswamy, K., Masand, P. S., & Nasrallah, H. A. (2006) · Annals of Clinical Psychiatry · doi:10.1080/10401230600801234 · Cited by 77
Antipsychotics and Diabetes: An Age-Related Association
Hammerman, A., Dreiher, J., Klang, S. H., Munitz, H., Cohen, A. D., & Goldfracht, M. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l015 · Cited by 75
Psychiatric Diagnosis as an Independent Risk Factor for Metabolic Disturbances
van Winkel, R., van Os, J., Ćelić, I., Eyck, D. V., Wampers, M., Scheen, A. J., Peuskens, J., & Binder, M. D. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0817 · Cited by 74
Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism
Oh, K., Park, J., Lee, S. Y., Hwang, I., Kim, J. B., Park, T., Lee, H., & Koo, S. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00502.2010 · Cited by 68
Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP)
Thomas, S. H. L., Drici, M. D., Hall, G. C., Crocq, M. A., Everitt, B., Lader, M. H., Jeunne, C. L., Naber, D., Priori, S., Sturkenboom, M., et al. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01563.x · Cited by 67
Increased Prevalence of Obesity and Glucose Intolerance in Youth Treated with Second—Generation Antipsychotic Medications
Panagiotopoulos, C., Ronsley, R. J., & Davidson, J. (2009) · The Canadian Journal of Psychiatry · doi:10.1177/070674370905401104 · Cited by 67
Atypical Antipsychotic Drugs and Diabetes Mellitus in the US Food and Drug Administration Adverse Event Database: A Systematic Bayesian Signal Detection Analysis
Baker, R. A., Pikalov, A., Tran, Q.-V., Kremenets, T., Arani, R. B., & Doraiswamy, P. M. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4092 · Cited by 66
Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder
Binder, M. D., Kalnická, D., van Winkel, R., Wampers, M., Hanssens, L., Eyck, D. V., Scheen, A. J., & Peuskens, J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1208 · Cited by 66
MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study
van Winkel, R., Moons, T., Peerbooms, O., Rutten, B. P. F., Peuskens, J., Claes, S. J., van Os, J., & Binder, M. D. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833bc60d · Cited by 59
Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia.
Hanssens, L., Binder, M. D., Kalnická, D., van Winkel, R., Wampers, M., Eyck, D. V., Scheen, A. J., & Peuskens, J. (2007) · PubMed · doi:10.1097/yic.0b013e3280113d3b · Cited by 57
Prediabetes in Patients Treated With Antipsychotic Drugs
Manu, P., Correll, C. U., van Winkel, R., Wampers, M., & Binder, M. D. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06822 · Cited by 54
Triglyceride/High-Density Lipoprotein Cholesterol Ratio
Fan, X., Liu, E. Y., Hoffman, V., Potts, A. J., Sharma, B., & Henderson, D. C. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05107yel · Cited by 52
A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study
Bhargava, A. (2003) · Population Health Metrics · doi:10.1186/1478-7954-1-3 · Cited by 50
Mechanisms and Genetics of Antipsychotic-Associated Weight Gain
Balt, S., Galloway, G., Baggott, M. J., Schwartz, Z., & Mendelson, J. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.97 · Cited by 47
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.
Bushe, C., & Leonard, B. E. (2007) · PubMed · Cited by 43
The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine release
Johnson, D. E., Nedza, F. M., Spracklin, D. K., Ward, K. M., Schmidt, A. W., Iredale, P. A., Godek, D. M., & Rollema, H. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.11.015 · Cited by 42
Blood Glucose and Schizophrenia
Bushe, C., & Leonard, B. E. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1107 · Cited by 38
The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology
Binder, M. D., Mauri, M., Shaw, K., Wetterling, T., Doble, A., Giudicelli, A., & Falissard, B. (2010) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.322 · Cited by 36
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs
Moons, T., Claes, S. J., Martens, G. J. M., Peuskens, J., van Loo, K. M. J., van Schijndel, J. E., Binder, M. D., & van Winkel, R. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.10.008 · Cited by 33
Cardiovascular Risk Assessment and Management in Mental Health Clients: Whose Role is it Anyway?
Wheeler, A., Harrison, J., Mohini, P., Nardan, J., Tsai, A., & Tsai, E. (2009) · Community Mental Health Journal · doi:10.1007/s10597-009-9237-0 · Cited by 32
Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
Taylor, D. M., & Bishara, D. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5742 · Cited by 30
QT Interval Duration and Dispersion in Children and Adolescents Treated With Ziprasidone
Correll, C. U., Lops, J. D., Figen, V., Malhotra, A. K., Kane, J. M., & Manu, P. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m05990yel · Cited by 29
Treatment decisions in major mental illness: weighing the outcomes.
Vreeland, B. (2007) · PubMed · Cited by 25
Focus on Ziprasidone
Green, B. (2001) · Current Medical Research and Opinion · doi:10.1185/030079901317010829 · Cited by 22
Antipsychotic‐associated all‐cause and cardiac mortality: what should we worry about and how should the risk be assessed?
Correll, C. U., & Nielsen, J. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01610.x · Cited by 20
How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications.
Elbe, D., & Savage, R. (2010) · PubMed · Cited by 13
Switching among Antipsychotics in Everyday Clinical Practice: Focus on Ziprasidone
Rossi, A., Cañas, F., Fagiolini, A. M., Larmo, I., Levy, P., Montes, J. M. G., Papageorgiou, G., Sturlason, R., Zink, M., & Correll, C. U. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2255 · Cited by 13
Weighing the outcomes
Russo, M. J., & Balekdjian, D. (2008) · Nature Biotechnology · doi:10.1038/nbt0208-173 · Cited by 9

Flagged first, then by citations

1 of the 131 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Citrome, L. Risk–benefit analysis of available treatments for schizophrenia. Psychiatric Times 1, 27–30 (2007).

Sorted by citations

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: A large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls
Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa‐Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., et al. (2017) · World Psychiatry · doi:10.1002/wps.20420 · Cited by 1,729
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis
Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271
Self-citation
Schizophrenia
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer‐Lindenberg, A., Weinberger, D. R., Cannon, T. D., O’Donovan, M. C., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,163
A review of depression and suicide risk assessment using speech analysis
Cummins, N., Scherer, S. J., Krajewski, J., Schnieder, S., Epps, J., & Quatieri, T. F. (2015) · Speech Communication · doi:10.1016/j.specom.2015.03.004 · Cited by 1,051

See all 1,145

Authors: De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U.
Affiliations: KU Leuven (BE)
Zucker Hillside Hospital (US)
ORCID: Detraux, Johan
Correll, Christoph U.
Venue: Nature Reviews Endocrinology
Publisher: Springer Science and Business Media LLC
Published: 2011-10-18
Volume: 8
Issue: 2
Pages: 114-126
ISSN: 1759-5029 (ISSN-L)
1759-5037
DOI: 10.1038/nrendo.2011.156
OpenAlex: W2014026290
Cited by: 1,145
References: 131
Citations by year: 2026: 85 · 2025: 75 · 2024: 62 · 2023: 91 · 2022: 97 · 2021: 99 · 2020: 84 · 2019: 77 · 2018: 73 · 2017: 85 · 2016: 74 · 2015: 75 · 2014: 65 · 2013: 52 · 2012: 44
FWCI: 6.96
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Endocrinology (publishedVersion)
PubMed (publishedVersion)
Research Publications (Maastricht University) (submittedVersion)
Lirias (KU Leuven) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Keywords: antipsychotic drugs, type 2 diabetes, cardiovascular disease, metabolic side effects, obesity, hyperglycemia, dyslipidemia, metabolic syndrome, QT prolongation, sudden cardiac death, glucose metabolism, lipid metabolism, health care disparities, screening and monitoring
MeSH terms: Adult, Cardiovascular Diseases, Child, Diabetes Mellitus, Humans, Metabolic Diseases, Antipsychotic Agents, Weight Gain, Death, Sudden, Cardiac

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks